Company Profile

Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).

Employees

Sector

Biotechnology & Medical Research

More about the company

31/01/24	Aravive, Inc.(NasdaqGS:ARAV) dropped from S&P TMI Index	CI
26/01/24	Aravive, Inc.(NasdaqGS:ARAV) dropped from NASDAQ Composite Index	CI
20/01/24	Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	MT
18/01/24	Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market	MT
18/01/24	Aravive, Inc. Announces Termination of Rudy C. Howard as Chief Financial Officer	CI
18/01/24	Aravive, Inc. Announces Termination of Gail McIntrye as Chief Executive Officer	CI
18/01/24	Aravive, Inc. Announces Board and Committee Resignations	CI
10/11/23	Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
22/08/23	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
22/08/23	Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
04/08/23	Top Midday Decliners	MT
03/08/23	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
03/08/23	HC Wainwright Downgrades Aravive to Neutral From Buy	MT

22/08/23	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
03/08/23	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
03/08/23	HC Wainwright Downgrades Aravive to Neutral From Buy	MT
03/08/23	William Blair Downgrades Aravive to Market Perform From Outperform	MT
03/08/23	BTIG Downgrades Aravive to Neutral From Buy	MT

18/01/24	Aravive, Inc. to Delist from The Nasdaq Stock Market	AQ
19/10/23	The Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZ	AQ
03/08/23	Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer	AQ
28/07/23	Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023	AQ
14/07/23	Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023	AQ

Manager	Title	Age	Since
Marek Ciszewski IRC	Investor Relations Contact	-	-
Maria Petrini PRN	Corporate Officer/Principal	-	10/04/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/4/23	Maria Petrini	Free	Executive/Senior Manager	400,000	0.6684%
1/2/23	Robert B. Geller	Free	Chief Technology Officer	400,000	0.6686%
1/2/23	Rudy Howard	Free	Chief Financial Officer	400,000	0.6686%

Aravive, Inc. Stock

Stocks

ARAV

US03890D1081

Biotechnology & Medical Research

Latest news : Aravive, Inc.

Analysts' recommendations: Aravive, Inc.

Press Releases: Aravive, Inc.

Quotes and Performance

Managers and Directors: Aravive, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARAVIVE, INC.	-13.39%	-23.18%	-	-	2.95M
ARGENX SE	+0.21%	-0.79%	+53.17%	+57.39%	53.79B
WUXI APPTEC CO., LTD.	+5.37%	+3.31%	+50.39%	+83.65%	54.69B
INSMED INCORPORATED	-1.20%	-1.94%	+4.35%	+402.68%	23.2B
BIONTECH SE	+0.74%	+2.32%	-16.23%	-14.44%	23.31B
WUXI BIOLOGICS (CAYMAN) INC.	+2.93%	+2.98%	+40.50%	-3.34%	20.03B
GENMAB A/S	-1.18%	-2.97%	+30.12%	-33.30%	17.31B
PHARMAESSENTIA CORPORATION	-1.67%	-6.00%	+163.95%	+284.69%	14.99B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.60%	+1.77%	+34.27%	+580.54%	15.36B
EXELIXIS, INC.	-0.70%	-0.91%	+24.87%	+179.47%	13.96B
Average	-0.84%	-0.71%	+42.82%	+170.81%	26.29B
Weighted average by Cap.	+1.29%	-0.93%	+42.27%	+134.03%